25 Apr 2024
19:00 CEST |
OXURION |
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
|
20103010 Biotechnology |
- |
15 Apr 2024
17:16 CEST |
OXURION |
Publication Annual Report – Annual Shareholders' Meeting
|
20103010 Biotechnology |
- |
11 Apr 2024
19:00 CEST |
OXURION |
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC
|
20103010 Biotechnology |
- |
10 Apr 2024
19:00 CEST |
OXURION |
Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Program : Eleventh tranche fully issued and paid-up
|
20103010 Biotechnology |
- |
05 Apr 2024
14:00 CEST |
OXURION |
Postponement Annual Shareholders Meeting - Amendment financial calendar
|
20103010 Biotechnology |
- |
28 Mar 2024
19:00 CET |
OXURION |
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
|
20103010 Biotechnology |
- |
27 Mar 2024
19:00 CET |
OXURION |
Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas - Amended version
|
20103010 Biotechnology |
- |
26 Mar 2024
19:00 CET |
OXURION |
Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas
|
20103010 Biotechnology |
- |
25 Mar 2024
19:10 CET |
OXURION |
OXURION announces its presence at the Paris SmallCap event on March 28, 2024.
|
20103010 Biotechnology |
- |
22 Mar 2024
19:00 CET |
OXURION |
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
|
20103010 Biotechnology |
- |
21 Mar 2024
19:00 CET |
OXURION |
Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas
|
20103010 Biotechnology |
- |
13 Mar 2024
19:00 CET |
OXURION |
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
|
20103010 Biotechnology |
- |
07 Mar 2024
19:00 CET |
OXURION |
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
|
20103010 Biotechnology |
- |
05 Mar 2024
19:00 CET |
OXURION |
Oxurion Receives EUR 300,000 in the framework of the Atlas Funding Program Tenth tranche fully issued and paid-up
|
20103010 Biotechnology |
- |
04 Mar 2024
19:00 CET |
OXURION |
Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas
|
20103010 Biotechnology |
- |
22 Jan 2024
22:02 CET |
OXURION |
Oxurion Announces New Strategic Orientation to De-risk and Diversify
|
20103010 Biotechnology |
- |
19 Jan 2024
19:00 CET |
OXURION |
Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas
|
20103010 Biotechnology |
- |
17 Jan 2024
19:00 CET |
OXURION |
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
|
20103010 Biotechnology |
- |
12 Jan 2024
08:00 CET |
OXURION |
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
|
20103010 Biotechnology |
- |
28 Dec 2023
21:15 CET |
OXURION |
Oxurion Avoids Bankruptcy, Announces Board and Management Changes and Enters into Binding Letter of Intent with its Main Creditor Atlas
|
20103010 Biotechnology |
- |
01 Dec 2023
19:00 CET |
OXURION |
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC
|
20103010 Biotechnology |
- |
20 Nov 2023
07:00 CET |
OXURION |
Oxurion Discloses Topline Data from KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema
|
20103010 Biotechnology |
- |
19 Nov 2023
21:00 CET |
OXURION |
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
|
20103010 Biotechnology |
- |
16 Nov 2023
19:00 CET |
OXURION |
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
|
20103010 Biotechnology |
- |
16 Nov 2023
19:00 CET |
OXURION |
Oxurion Receives EUR 1.0 Million under Amended Atlas Funding Program Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Reach Topline Data from KALAHARI Trial This Year
|
20103010 Biotechnology |
- |
15 Nov 2023
19:00 CET |
OXURION |
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
|
20103010 Biotechnology |
- |
06 Nov 2023
20:00 CET |
OXURION |
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
|
20103010 Biotechnology |
- |
03 Nov 2023
20:00 CET |
OXURION |
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
|
20103010 Biotechnology |
- |
30 Oct 2023
08:00 CET |
OXURION |
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC
|
20103010 Biotechnology |
- |
25 Oct 2023
08:00 CEST |
OXURION |
Oxurion Receives EUR 1.5 Million under Amended Atlas Funding Program; Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Achieve Topline Data from KALAHARI Trial
|
20103010 Biotechnology |
- |
20 Oct 2023
20:01 CEST |
OXURION |
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
|
20103010 Biotechnology |
- |
20 Oct 2023
20:00 CEST |
OXURION |
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC
|
20103010 Biotechnology |
- |
10 Oct 2023
20:00 CEST |
OXURION |
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
|
20103010 Biotechnology |
- |
03 Oct 2023
19:00 CEST |
OXURION |
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
|
20103010 Biotechnology |
- |
29 Sep 2023
19:00 CEST |
OXURION |
Oxurion Publishes First Half 2023 Results
|
20103010 Biotechnology |
- |
27 Sep 2023
19:00 CEST |
OXURION |
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
|
20103010 Biotechnology |
- |
18 Sep 2023
08:04 CEST |
OXURION |
Oxurion Receives First EUR 1 Million under Amended Atlas Funding Program
|
20103010 Biotechnology |
- |
18 Sep 2023
08:02 CEST |
OXURION |
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
|
20103010 Biotechnology |
- |
18 Sep 2023
08:00 CEST |
OXURION |
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC
|
20103010 Biotechnology |
- |
11 Sep 2023
08:00 CEST |
OXURION |
Oxurion Announces Key Amendments to Atlas and Kreos/Pontifax Agreements Enabling KALAHARI Trial to Progress to Topline Results in 2023
|
20103010 Biotechnology |
- |
07 Sep 2023
19:00 CEST |
OXURION |
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
|
20103010 Biotechnology |
- |
01 Sep 2023
19:00 CEST |
OXURION |
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
|
20103010 Biotechnology |
- |
01 Sep 2023
19:00 CEST |
OXURION |
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
|
20103010 Biotechnology |
- |
25 Aug 2023
22:00 CEST |
OXURION |
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
|
20103010 Biotechnology |
- |
23 Aug 2023
20:05 CEST |
OXURION |
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
|
20103010 Biotechnology |
- |
23 Aug 2023
20:00 CEST |
OXURION |
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC
|
20103010 Biotechnology |
- |
21 Aug 2023
19:05 CEST |
OXURION |
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
|
20103010 Biotechnology |
- |
21 Aug 2023
19:00 CEST |
OXURION |
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
|
20103010 Biotechnology |
- |
16 Aug 2023
19:00 CEST |
OXURION |
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
|
20103010 Biotechnology |
- |
11 Aug 2023
08:08 CEST |
OXURION |
Oxurion Receives Funding of EUR One Million under Atlas Special Opportunities LLC (Atlas) Funding Program
|
20103010 Biotechnology |
- |